A detailed history of Eulav Asset Management transactions in Dexcom Inc stock. As of the latest transaction made, Eulav Asset Management holds 89,013 shares of DXCM stock, worth $10.1 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
89,013
Previous 98,000 9.17%
Holding current value
$10.1 Million
Previous $12.2 Million 1.53%
% of portfolio
0.34%
Previous 0.38%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 30, 2024

SELL
$114.22 - $140.1 $1.03 Million - $1.26 Million
-8,987 Reduced 9.17%
89,013 $12.3 Million
Q4 2023

Feb 14, 2024

SELL
$75.49 - $124.16 $150,980 - $248,320
-2,000 Reduced 2.0%
98,000 $12.2 Million
Q3 2023

Nov 13, 2023

BUY
$86.06 - $137.93 $1.89 Million - $3.03 Million
21,938 Added 28.1%
100,000 $9.33 Million
Q2 2023

Aug 09, 2023

SELL
$112.47 - $130.98 $1.23 Million - $1.43 Million
-10,938 Reduced 12.29%
78,062 $10 Million
Q1 2023

Apr 27, 2023

BUY
$104.0 - $122.92 $312,000 - $368,760
3,000 Added 3.49%
89,000 $10.3 Million
Q4 2022

Feb 14, 2023

SELL
$84.98 - $122.67 $3.06 Million - $4.42 Million
-36,000 Reduced 29.51%
86,000 $9.74 Million
Q3 2022

Nov 03, 2022

BUY
$76.35 - $94.18 $763,500 - $941,800
10,000 Added 8.93%
122,000 $9.83 Million
Q2 2022

Jul 22, 2022

BUY
$67.99 - $132.89 $6.32 Million - $12.4 Million
93,000 Added 489.47%
112,000 $8.35 Million
Q1 2022

May 10, 2022

SELL
$94.08 - $130.2 $564,480 - $781,199
-6,000 Reduced 24.0%
19,000 $9.72 Million
Q4 2021

Feb 11, 2022

SELL
$129.87 - $162.82 $1.82 Million - $2.28 Million
-14,000 Reduced 35.9%
25,000 $13.4 Million
Q3 2021

Nov 15, 2021

SELL
$106.71 - $143.18 $1.28 Million - $1.72 Million
-12,000 Reduced 23.53%
39,000 $21.3 Million
Q2 2021

Aug 06, 2021

BUY
$80.99 - $107.93 $809,900 - $1.08 Million
10,000 Added 24.39%
51,000 $21.8 Million
Q4 2020

Feb 16, 2021

BUY
$78.0 - $104.5 $312,000 - $418,000
4,000 Added 10.81%
41,000 $15.2 Million
Q3 2020

Nov 05, 2020

SELL
$95.51 - $112.95 $47,755 - $56,475
-500 Reduced 1.33%
37,000 $15.3 Million
Q2 2020

Aug 11, 2020

SELL
$62.68 - $105.34 $814,840 - $1.37 Million
-13,000 Reduced 25.74%
37,500 $15.2 Million
Q1 2020

Apr 27, 2020

SELL
$47.79 - $75.63 $645,165 - $1.02 Million
-13,500 Reduced 21.09%
50,500 $13.6 Million
Q4 2019

Feb 13, 2020

SELL
$36.62 - $57.29 $329,580 - $515,610
-9,000 Reduced 12.33%
64,000 $14 Million
Q3 2019

Nov 12, 2019

SELL
$35.53 - $43.8 $1.1 Million - $1.36 Million
-31,000 Reduced 29.81%
73,000 $10.9 Million
Q2 2019

Aug 05, 2019

BUY
$27.84 - $38.92 $1.06 Million - $1.48 Million
38,000 Added 57.58%
104,000 $15.6 Million
Q4 2018

Feb 14, 2019

SELL
$26.99 - $37.37 $242,910 - $336,330
-9,000 Reduced 12.0%
66,000 $7.91 Million
Q3 2018

Oct 26, 2018

SELL
$23.35 - $36.72 $116,750 - $183,600
-5,000 Reduced 6.25%
75,000 $10.7 Million
Q2 2018

Aug 14, 2018

SELL
$17.54 - $25.22 $17,540 - $25,220
-1,000 Reduced 1.23%
80,000 $7.6 Million
Q1 2018

May 09, 2018

SELL
$13.06 - $18.54 $274,260 - $389,340
-21,000 Reduced 20.59%
81,000 $6.01 Million
Q4 2017

Feb 14, 2018

SELL
$11.12 - $15.38 $88,960 - $123,040
-8,000 Reduced 7.27%
102,000 $5.85 Million
Q3 2017

Nov 14, 2017

BUY
$11.36 - $18.98 $227,200 - $379,600
20,000 Added 22.22%
110,000 $5.38 Million
Q2 2017

Aug 14, 2017

BUY
N/A
90,000
90,000 $6.58 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $43.8B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Eulav Asset Management Portfolio

Follow Eulav Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eulav Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Eulav Asset Management with notifications on news.